Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel <i>EGFR</i> Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases.

Front Oncol · 2021 · PMC8573166 · PMID 34760695

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Compared to erlotinib alone, the combination also had a positive trend to prolong OS in this patient subgroup.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.